



## Signing of Strategic Platform License

January 30, 2024 1:05 PM EST

RNS Number : 3812B

MaxCyte, Inc.

30 January 2024

### **MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen's Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers**

*Wugen to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support its programs for hematologic and solid tumor cancers*

**ROCKVILLE, MD, and ST LOUIS, MO, Jan. 30, 2024** - [MaxCyte, Inc.](#), (Nasdaq: MXCT; LSE: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, and Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced the signing of a strategic platform license (SPL).

Under the terms of the agreement, Wugen gains non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform. In return, MaxCyte will receive annual license fees and program-related revenue.

Wugen is developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer. The company's investigational cell therapies originate from healthy donors and are further engineered to enhance their function of eliminating cancer cells. Wugen's lead program is evaluating WU-CART-007, a CD7 targeted CAR-T cell therapy, in a global Phase 1/2 clinical trial for the treatment of relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL)/lymphoblastic lymphoma (LBL) in adolescent and adult patients. WU-CART-007 has received Orphan Drug, Fast Track, and Rare Pediatric Disease Designations from the U.S. Food and Drug Administration for the treatment of R/R T-ALL/LBL. Additional information is available on [clinicaltrials.gov](#), identifier NCT# 04984356.

"As WU-CART-007 is transferred onto the ExPERT platform and continues to progress in the clinic, we are able to support efficient and seamless expansion to large-scale manufacturing," **said Maher Masoud, President and CEO of MaxCyte.** "By working with MaxCyte, Wugen can maximize the number of doses in each manufacturing run for later stage clinical development and potential commercial phase."

"Our partnership with MaxCyte is an exciting step in advancing our groundbreaking therapies for difficult-to-treat cancers," **said Kumar Srinivasan, PhD, MBA, President and CEO of Wugen.** "This collaboration brings us even closer to delivering life-saving treatments to patients with limited options. With MaxCyte's expertise, we're in a position to expedite progress through crucial development stages and make a significant impact on patients' lives."

MaxCyte's EXPERT™ instrument portfolio represents the next generation of clinically validated electroporation technology for complex and scalable cell engineering. Offering high transfection efficiency, seamless scalability, and enhanced functionality, the EXPERT™ platform is crucial for enabling the next wave of biological and cellular therapeutics. Wugen is MaxCyte's 26<sup>th</sup> clinical/commercial partnership overall, each of which generates pre-commercial milestone revenue, the vast majority of which includes sales-based payments.

#### **About MaxCyte**

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our EXPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The EXPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at [maxcyte.com](http://maxcyte.com) and follow us on [X](#) (formerly Twitter) and [LinkedIn](#).

#### **About Wugen**

Wugen, Inc. is a clinical-stage biotechnology company developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer. Wugen is leveraging its proprietary Moneta™ platform and deep genomic engineering expertise to pioneer a new class of memory NK cell therapies to treat hematological and solid tumor malignancies. For more information, please visit <https://wugen.com/>

#### **MaxCyte Contacts:**

##### ***US IR Adviser***

##### ***Gilmartin Group***

David Deuchler, CFA

+1 415-937-5400

[ir@maxcyte.com](mailto:ir@maxcyte.com)

##### ***US Media Relations***

##### ***Spectrum Seismic Collaborative***

Valerie Enes

+1 408-497-8568

[venes@spectrumscience.com](mailto:venes@spectrumscience.com)

##### ***Nominated Adviser and Joint Corporate Broker***

Panmure Gordon

Emma Earl / Freddy Crossley

Corporate Broking  
Rupert Dearden  
+44 (0)20 7886 2500

***UK IR Adviser***

***ICR Consilium***

Mary-Jane Elliott  
Chris Welsh  
+44 (0)203 709 5700  
[maxcyte@consilium-comms.com](mailto:maxcyte@consilium-comms.com)

**Wugen Contacts:**

***Investor Contact***

Mark Lewis  
+1 314-501-1968  
[MLEWIS@WUGEN.COM](mailto:MLEWIS@WUGEN.COM)

***Media Contact***

Christine Fanelle  
Scient PR  
+1 215-595-5211  
[christine@scientpr.com](mailto:christine@scientpr.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rs@lse.com](mailto:rs@lse.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCBMMMTMTJBJI